Vertex and CRISPR Therapeutics Received MHRA’s Authorization for Casgevy to Treat Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Shots:
- The MHRA granted conditional marketing authorization to Casgevy (exagamglogene autotemcel) for the treatment of patients aged ≥12yrs. with sickle cell disease (SCD) & transfusion-dependent beta thalassemia (TDT)
- The conditional marketing authorization was based on the data from two global clinical trials evaluating Casgevy in SCD with recurrent VOCs & TDT the results for which depicted that the trials met their 1EP of becoming free from severe VOCs or transfusion independent for at least 12 consecutive months
- Earlier, Casgevy or exa-cel (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy, was granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA in the UK
Ref: Businesswire | Image: vertex
Related News:- Vertex Entered into a Non-Exclusive License Agreement with CRISPR Therapeutics to Advance Hypoimmune Cell Therapies for Type 1 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
